Compare · MEDP vs MXCT
MEDP vs MXCT
Side-by-side comparison of Medpace Holdings Inc. (MEDP) and MaxCyte Inc. (MXCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MEDP and MXCT operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $15.36B, about 115.6x MXCT ($132.8M).
- Over the past year, MEDP is up 72.2% and MXCT is down 38.9% - MEDP leads by 111.1 points.
- MXCT has been more active in the news (9 items in the past 4 weeks vs 5 for MEDP).
- MEDP has more recent analyst coverage (25 ratings vs 11 for MXCT).
- Company
- Medpace Holdings Inc.
- MaxCyte Inc.
- Price
- $537.63-0.04%
- $1.24-8.49%
- Market cap
- $15.36B
- $132.8M
- 1M return
- +16.40%
- +9.73%
- 1Y return
- +72.22%
- -38.92%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- 2021
- News (4w)
- 5
- 9
- Recent ratings
- 25
- 11
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
MaxCyte Inc.
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Latest MEDP
- Medpace downgraded by Robert W. Baird with a new price target
- Medpace downgraded by Jefferies with a new price target
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.27% to 10,352 units (SEC Form 4)
- Director Kraft Robert O. converted options into 33 shares, increasing direct ownership by 4% to 955 units (SEC Form 4)
- Director Carley Brian T converted options into 36 shares, increasing direct ownership by 0.11% to 32,825 units (SEC Form 4)
- Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
- New insider Hansman Brad W. claimed ownership of 697 shares (SEC Form 3)
- SEC Form 8-K filed by Medpace Holdings Inc.
- General Counsel & Corp. Secy. Ewald Stephen P exercised 16,349 shares at a strike of $138.87 and sold $7,357,050 worth of shares (16,349 units at $450.00) (SEC Form 4)
- SEC Form 8-K filed by Medpace Holdings Inc.
Latest MXCT
- MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
- Director Johnston John Joseph was granted 30,421 shares, increasing direct ownership by 18% to 201,581 units (SEC Form 4)
- Director Hemrajani Rekha was granted 30,421 shares, increasing direct ownership by 76% to 70,314 units (SEC Form 4)
- Director Erck Stanley C was granted 30,421 shares, increasing direct ownership by 8% to 428,749 units (SEC Form 4)
- Director Douglas Richard was granted 30,421 shares, increasing direct ownership by 13% to 260,998 units (SEC Form 4)
- Director Collins Cynthia was granted 30,421 shares, increasing direct ownership by 38% to 111,310 units (SEC Form 4)
- Director Brooke William W was granted 30,421 shares, increasing direct ownership by 20% to 181,300 units (SEC Form 4)
- Director Balthrop Patrick J was granted 30,421 shares, increasing direct ownership by 60% to 80,998 units (SEC Form 4)
- Director Al-Wakeel Yasir B. was granted 30,421 shares, increasing direct ownership by 60% to 80,998 units (SEC Form 4)
- MaxCyte Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders